In Ph-positive (Ph þ ) leukemia, the quiescent cell state is one of the reasons for resistance to the BCR-ABL-kinase inhibitor, imatinib. In order to examine the mechanisms of resistance due to quiescence and the effect of the mammalian target of rapamycin inhibitor, everolimus, for such a resistant population, we used Ph þ acute lymphoblastic leukemia patient cells serially xenotransplanted into NOD/SCID/IL2rc null (NOG) mice. Spleen cells from leukemic mice showed a higher percentage of slow-cycling G 0 cells in the CD34
Introduction
Marked clinical improvement was reported when a BCR-ABLkinase inhibitor, imatinib, was combined with chemotherapy for the treatment of Ph-positive (Ph þ ) acute lymphoblastic leukemia (ALL).
1,2 However, further improvement is needed to decrease relapses owing to residual or resistant leukemic cells. Leukemia stem cells (LSCs) are reported to be responsible for leukemia relapse. 3 Mathematical models of the chronic phase of chronic myeloid leukemia suggested that imatinib does not eradicate LSCs, 4, 5 and the survival of malignant cells is reportedly attributable to the quiescence of LSCs. 6 In order to overcome drug resistance, rational combinations of molecular targeting drugs of different signal pathways have been explored. 7 The mammalian target of rapamycin (mTOR) has attracted attention as a therapeutic target of LSCs. 8, 9 mTOR regulates cell growth and apoptosis through the phosphatidilinositide-3-kinase (PI3K)/AKT/mTOR pathway, which was reported to be constitutively activated in most AMLs 10 or in T-ALL cell lines. 11 The inhibitory effect of an mTOR inhibitor, rapamycin, on the Ph þ leukemia cell lines with T315I was reported, 7 and more recently, the effect of everolimus (RAD001) on human childhood B-cell progenitor ALL was reported in a non-obese diabetic/severe combined immunodeficiency (NOD/ SCID) model. 12 The mTOR inhibitor everolimus is an orally available mTOR inhibitor which was approved by the Food and Drug Administration for advanced renal cell carcinoma. A phase I/II study has been performed in patients with acute leukemia, 13 and clinical trials alone or in combination with other drugs are also currently ongoing for lymphoma and myeloma.
14 Effects of everolimus on human Ph þ ALL have not been well examined. In this study, we examined the efficacy of everolimus in combination with imatinib utilizing Ph þ ALL cell lines and an NOD/SCID/IL2rg null (NOG) mouse model of human BCR-ABL þ leukemia, 15 in which the hierarchy of leukemia cells was maintained.
Materials and methods

Leukemic cells
Xenografts were established in NOD/SCID/IL2rg null (NOG) mice as previously described. 15 Briefly, Ph þ ALL patient cells were serially xenotransplanted into immunodeficient NOG mice, and engrafted spleen cells were obtained 8-10 weeks after injection. Erythrocytes were removed by erythrocyte lysis buffer (EL-buffer; Qiagen, Hilden, Germany), and the remaining leukemic cells were preserved in liquid nitrogen until use. Leukemic repopulated cells were thawed and washed, resuspended in RPMI containing 10% fetal bovine serum, 5 mM MgCl 2 and 0.2 mg/ml DNase I (Roche Diagnostics, Mannheim, Germany) and incubated at 37 1C for 10 min. Cells were washed and resuspended at 1 million cells per ml in RPMI containing 20% fetal bovine serum with cytokines (human stem cell factor, 50 ng/ml, human interleukin-3 20 ng/ml and human granulocyte/macrophage-colony-stimulating factor, 20 ng/ml), and incubated with imatinib for 48 h at 37 1C in a CO 2 incubator. In an in vitro long-term culture, spleen (SP) cells derived from leukemic NOG mice were co-cultured with S17 stromal cells and treated with imatinib and everolimus. 16 S-17 cells and leukemic cells were passaged twice weekly.
Reagents
Everolimus and imatinib were supplied by Novartis Institutes for Biomedical Research (Basel, Switzerland). Imatinib was dissolved in dH 2 O and used for in vitro and in vivo experiments.
Everolimus was stored as 10 À2 M stock solution in dimethylsulfoxide for an in vitro experiment. For in vivo experiments, everolimus was formulated at 2% (wt/wt) in a microemulsion vehicle. Aliquots of everolimus and control vehicle were stored at À20 1C.
Immunoblotting
Antibodies against the phospho(p)-Abl (Tyr245), p-CrkL (Tyr207), p-mTOR (Ser2448), p-p70 S6 kinase (Thr389), p-4EBP1 (Thr37/46), MCL-1, p-AKT (Ser473), AKT and p-FOXO1(Thr24)/FoxO3a(Thr32) were from Cell Signaling (Boston, MA, USA). Immunoblotting was performed with the standard protocols as previously described. 17 Flow cytometric analysis and cell sorting After the treatment period, cells were washed at 4 1C and then stained with anti-CD34-allophycocyanin (APC), anti-CD38-PECy7 (Becton Dickinson, San Jose, CA, USA), and anti-CD45-APC-Alexa Fluor 750 (Invitrogen, Carlsbad, CA, USA) antibodies (1:100) for 30 min on ice. Cells were subsequently labeled with annexin-V-fluorescein isothiocyanate and propidium iodide (PI) according to the manufacturer's protocol (Annexin-V-FLUOS Staining Kit; Roche Diagnostics). The cells were acquired by FACS Aria (Becton Dickinson) and analyzed by Flow Jo software. DNA contents analysis was assessed using the standard procedure as previously described. 18 For CD34 þ selection, leukemic cells were subjected to immunomagnetic separation using a MACS CD34 MicroBead Kit (Miltenyi Biotech, Auburn, CA, USA) following the manufacturer's recommendations. The collected cells were applied to a second column and the purification step was repeated. Staining of cells with Hoechst 33342 (Sigma, St Louis, MO, USA) with PyroninY (Polysciences, Warrington, PA, USA) was performed as previously described. 19 Briefly, thawed leukemic spleen cells were separated with the MACS CD34 MicroBead Kit (Miltenyi Biotech) into CD34 þ cells and flow-through cells containing CD34 À cells. MACS-separated cells or drug-treated cells on S17 were washed and stained with Hoechst 33342 and PyroninY, and washed at 4 1C. MACS-separated CD34 þ cells were then stained with anti-CD38-APC, and flow-through cells containing CD34 À cells were stained with anti-CD34-APC. Flow cytometric analysis was performed using FACS Aria.
For cell sorting, leukemic spleen cells were stained with anti-CD34-APC, anti-CD38-PE-Cy7 and anti-CD45-APC-Cy7 antibodies and labeled with PI. PI À CD45 þ cells were sorted for CD34 and CD38 expression using FACS Aria, incubated with treatment drugs for 6 h at 37 1C in a CO 2 incubator as described above.
Mouse models Humanized leukemic mouse model. NOG and NOD/SCID mice were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan) and Clea Japan (Tokyo, Japan), respectively. Seven-week-old male NOD/SCID mice received 2 Gy of total body irradiation from an X-ray source (MBR-1520R-3; Hitachi Medico Technology Corporation, Tokyo, Japan), 24 h before administration of leukemic 2 Â 10 7 cells. Everolimus (5 mg/kg), imatinib (100 mg/kg) or vehicle were diluted with dH 2 O, and given daily at 10 ml/kg for 10 days by gavage. Bone marrow and spleen cells were stained with anti-human CD19-PE (Becton Dickinson) and anti-mouse CD45-PerCP, and acquired with FACS Aria to analyze chimerism. Cells were also stained with anti-CD34-APC, anti-CD38-PE-Cy7 and anti-CD45-APC-Alexa Fluor 750, and were subsequently labeled with annexin-Vfluorescein isothiocyanate and PI as explained above. Protocols were approved by the Nagoya University Animal Ethics Committee.
Histopathology
Livers, spleens and femurs were fixed in 15% buffered formalin. Hematoxylin and eosin, and CD34 staining were performed as previously described. [20] [21] [22] Slides were examined at room temperature and images were captured by a fluorescence microscope with a charge-coupled device camera (BZ-8000; Keyence, Osaka, Japan) fitted with Â 20 and Â 60 objective. Images were acquired by BZ-analyzer software (Keyence).
Statistical analysis
Differences among more than two groups were analyzed with the Bonferroni test followed by one-way analysis of variance. Statistical analyses were performed with STATA 9.2 software (StataCorp, College Station, TX, USA).
Results
Ex vivo treatment with imatinib for more residual
We analyzed the cell cycle status of untreated spleen cells derived from the humanized Ph þ ALL leukemia murine model reported previously. 15 In the CD34 þ CD38 À population, a higher percentage of Hoechst Treatment of CD34/CD38 sorted cells for 6 h with 3 mM imatinib caused equivalent inhibition of the phosphorylation of BCR-ABL and direct-substrate CrkL in each CD34/CD38 sub-population ( Figure 1d ). Inhibition of phosphorylation with imatinib (1 and 3.3 mM) was also observed with intracellular staining of phosphoCrkL (Supplementary Figure S1c) . Expressions of BCR-ABL and ABL were equivalent in each CD34/CD38 sub-population ( Figure 1d ). These results suggested that the slow-cycling population derived from Ph þ leukemia NOG mice was insensitive to imatinib in spite of BCR-ABL dephosphorylation.
Ex vivo effects of everolimus on leukemic spleen cells, alone and in combination with imatinib Furthermore, we have introduced S-17 murine stromal cell lines to support the leukemic spleen cells in order to assess longerterm effect of treatment drugs, 16 as the CD34 þ population of leukemic cells from the NOG mice eventually differentiated into CD34
À cells and could not be maintained only with cytokines (Figure 2a) . To examine the potential of everolimus to overcome resistance due to quiescence in Ph þ leukemia cells, everolimus treatment was investigated ex vivo alone and in combination with imatinib on S17 stromal cells. Everolimus treatment at 100 nM for 5 days increased the sub-G 1 population (14 vs 7.9%; control), and combination of everolimus (100 nM) and imatinib (1 mM) further increased the sub-G 1 population (68%, Figure 2b , upper panel). Cell cycle status was also investigated after þ 38 À population relative to dimethylsulfoxide control (Figure 2d, Supplementary Figure S1d) . These results indicated that ex vivo combination treatment with imatinib and everolimus was also effective for the quiescent CD34 þ 38 À cells.
Evaluation of molecular biomarkers during cell death induced by treatment with imatinib and everolimus
We next investigated the effects of imatinib and everolimus on BCR-ABL and mTOR signaling. Separated CD34 þ cells were treated with and without imatinib (1 mM) or everolimus (100 nM) for 4 h. After imatinib treatment, phosphorylation of BCR-ABL was clearly inhibited in each population, but it was not affected after everolimus treatment (Figure 3a) . After everolimus treatment, the phosphorylation of S6 K, which is a direct substrate of mTOR, was clearly inhibited; however, the phosphorylation of mTOR and 4EBP1 was not changed (Figure 3b ). These results imply that everolimus inhibited mTOR signaling of CD34 þ cells and induced cell death independently of the BCR-ABL signaling pathway. Both imatinib alone and in combined treatment inhibited phosphorylation of BCR-ABL. Conversely, everolimus alone and in combination both inhibited phosphorylation of S6 K in both CD34 þ 38 À and CD34 þ 38 þ sub-populations (Figure 3c) . Everolimus alone or in combination with imatinib decreased the expression of the antiapoptotic BCL-2 family protein, MCL-1, after 4 h, and the combination of everolimus and imatinib also decreased the expression of MCL-1, not BCL-2, after 12 h (Figure 3c ). These results implied that combination treatment with imatinib and everolimus induced cell death in quiescent Ph þ leukemia cells.
In vivo investigation of effects of everolimus, alone and in combination with imatinib
To elucidate the in vivo efficacy of everolimus treatment, its effects were investigated alone (5 mg/kg) and in combination with imatinib (100 mg/kg þ everolimus 5 mg/kg) using NOD/SCID mice intravenously injected with leukemic spleen cells from (Figure 4d ) and the total number of splenic human CD19 þ leukemic cells (Figure 4e ), was observed to be lowest in the imatinib-plus-everolimus-treated group. Immunohistochemistry showed that the combination of imatinib plus everolimus þ leukemic spleen cell numbers were relatively compared with the average of control (b-e: *Po0.001, **Po0.005 and ***Po0.05 by one-way analysis of variance followed by Bonferroni). (f) Hematoxylin and eosin (HE) staining (left panels) and immunohistochemical analysis with CD34 (right panels) of the spleen from control mice and imatinib and/or everolimus-treated mice were performed. A charge-coupled device camera provided images at approximately Â 100 of the original magnification.
Everolimus overcomes resistance in quiescent Ph
þ human leukemic cells in spleen, liver and bone marrow (Figure 4f, Supplementary Figure S2 ). Everolimus alone also decreased the percentage of G 0 cells in the CD34 þ leukemic cells of the treated bone marrow (Supplementary Figure S3 ). These results indicated the in vivo efficacy of everolimus treatment in a Ph þ leukemia murine model.
Discussion
In this study, we showed the effects of everolimus in combination with imatinib against Ph þ ALL quiescent cells. Ex vivo imatinib treatment of Ph þ leukemia cells from a humanized mouse model showed more residual cells in the CD34 þ CD38 À population, which contains significantly more quiescent cells. Our data showed an ex vivo effect against these residual cells, and the combination of imatinib and everolimus showed an in vivo effect. These data have shown the potential of everolimus to overcome imatinib resistance in quiescent cells. LSCs are reported to be responsible for the resistance to chemotherapy and molecular targeting agents. 23, 24 In chronic myeloid leukemia, non-proliferating quiescent CD34 þ cells have been found to be more resistant than proliferating leukemic cells after treatment with several chemotherapeutic agents. 25 Other studies have shown that inhibitors of mTOR with conventional therapies induced apoptosis and reduced LSCs. 8 The definition of LSCs or cancer stem cells is sometimes controversial in certain diseases. In human AML, LSCs have been phenotypically identified within a CD34 þ CD38 À fraction. 23, 26 In contrast, it is controversial whether ALL LSCs exist within the CD34 þ fraction and how CD34, CD38, CD19 and CD133 relate to ALL LSCs. 15, [27] [28] [29] In our current study, the potential of everolimus to overcome imatinib-resistant quiescent cells was demonstrated by using a humanized leukemic mouse model that maintains the differentiation hierarchy of Ph þ leukemia. 15 However, it cannot be determined at this point if the real LSCs of Ph þ ALL can be diminished until the LSCs in this disease category are clarified.
MCL-1, an antiapoptotic member of the BCL-2 protein family, reportedly regulates the self-renewal of human hematopoietic stem cells as well as LSCs. 30 Mills et al. 31 also reported that MCL-1 was translationally regulated by mTORC1. Together with these reports, our results showing decreased expression of MCL-1 by combination treatment of imatinib and everolimus suggested that the combination treatment induced cell death of quiescent Ph þ leukemia cells by interfering with the mitochondrial-mediated cell death pathway. Rapamycin and its analogs are also known to induce autophagic cell death, 32 and Bellodi et al. 33 reported that target autophagy potentiates tyrosine kinase-induced cell death in Ph þ leukemia cells. We are also investigating the relation of autophagy in cell death in our experimental systems.
In this study, everolimus treatment of Ph þ leukemia cells from a humanized mouse model decreased the phosphorylation of S6 K, but it increased the phosphorylation of AKT (Ser473) and FOXO1/3a (Supplementary Figure S4a) . Rapamycin and its analogs, such as everolimus and temsirolimus, are allosteric mTOR inhibitors that function at a distance from the adenosine triphosphate-catalytic binding site. Of the two cellular protein complexes of mTOR molecule, mTORC1 and mTORC2, mTORC1 is sensitive to these allosteric mTOR inhibitors and mTORC2 is resistant. 34 mTORC2 directly activates AKT, and this AKT activation in a feedback loop has been reported to correlate with rapamycin failure. 35 This feedback loop might also be related to our data on upregulated AKT.
Recently, a new generation of mTOR inhibitors has been developed. Dual PI3K/mTOR inhibitors, such as BEZ235, EX147 and PI-103, inhibit PI3 K and both small molecules of mTORC1/2.
36
Adenosine triphosphate-competitive mTOR inhibitors that selectively inhibit TORC1/2 molecules also have been reported to be effective against Ph þ transformed leukemia cells and to be less immunosuppressive than PI3K/mTOR inhibitors. 37 The effectiveness of a new generation of mTOR inhibitors should also be investigated in our future studies, in particular, the efficacy of these inhibitors against quiescent or leukemic stem cells using a humanized leukemic mouse model. However, it was suggested that dual PI3K/mTOR inhibitors may cause a greater degree of immune suppression by affecting normal cell functions.
14 Although we have examined the colony formation of CD34 þ human umbilical cord blood and it was suggested that everolimus did not severely interfere with hematopoietic colony formation (data not shown), the effects of everolimus and the new-generation mTOR inhibitors on normal cells and immune functions must be investigated in future studies.
Acquired mutation in the BCR-ABL gene also causes primary and secondary treatment failure in Ph þ leukemia. Our data suggest that imatinib-resistant cell lines with T315I mutation (Supplementary Figures S4b and c) can be inhibited with everolimus with downregulation of the mTOR pathway (Supplementary Figure S4d ). The in vivo effect of everolimus on T315I-mutated Ph þ leukemic cells is also indicated (Supplementary Figure S4e ). Further study is needed to determine the effect of everolimus on T315I-mutated leukemia, especially in combination with a T315I inhibitor such as AP24534 (ponatinib). 38 In conclusion, we have investigated the imatinib and everolimus combination effect against human Ph þ quiescent leukemic cells utilizing a mouse model. Everolimus can improve the treatment of resistant Ph þ leukemia. These mice also provide the opportunity to evaluate the effects of new therapeutic modalities on leukemic cells in different stages of cell cycle.
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